Chronic News and Research

RSS

KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates

Results from an ongoing surveillance study, PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology of the Ketolide Telithromycin – United States) Year 2 (2001-2002), suggest that KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates, including those resistant to other antimicrobial agents.

24 May 2004

Significant symptom relief reported in clinical trial patients with irritable bowel syndrome

Solvay Pharmaceuticals unveiled this week results from a six-month study of both male and female patients and from a subgroup analysis of males with Irritable Bowel Syndrome with Diarrhea predominance (IBS-D).

24 May 2004

Once-daily treatment with Alvesco (ciclesonide) in asthma patients has no effect on normal adrenal function

New data presented at the American Thoracic Society’s 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.

24 May 2004

Increases in co-payments may reduce the use of medications

Significant increases in co-payments may reduce the use of medications and raise concern about adverse health consequences, according to a study published in the May 19 issue of the Journal of the American Medical Association (JAMA).

22 May 2004

Helminthic therapy, using worm eggs to treat patients with inflammatory bowel disorders

University of Iowa Health Care researchers reported important findings recently at a conference of specialists in New Orleans, La. The findings are from their study of helminthic therapy - using specially prepared worm eggs - to treat patients diagnosed with inflammatory bowel disorders that don't respond to standard treatments.

21 May 2004

Using gene therapy to fight rheumatoid arthritis

Guided by a similar principle, arthritis researchers at the University of Florida and Harvard University hope to use gene therapy to help joint cells pump out a harmless protein that parks in receptor sites, leaving a notorious inflammatory agent “circling the lot” and unable to cause pain, swelling and possible joint damage.

21 May 2004

New treatment for dry eye syndrome (keratoconjunctivitis sicca)

Researchers in the department of ophthalmology at the University of Arizona College of Medicine in Tucson played an important role in the development of Restasis, the first alternative to artificial tears for the treatment of dry eye syndrome.

21 May 2004

Pulsed-dye laser surgery for voice disorders better all round

The newly developed pulsed-dye laser surgery for voice disorders has been found to be faster, cheaper, better tolerated, and less complicated than standard surgery that requires general anesthesia, more time and a longer recovery, surgeons reported here today at an international conference on problems associated with laryngopharyngeal reflux.

21 May 2004

Pacemaker-type device and medicines reduce hospital stays and death rates

A nationwide clinical trial of more than 1,600 heart failure patients showed that when medicines are combined with the use of a pacemaker-type device that resynchronizes both sides of the heart, hospital stays and death rates drop significantly.

20 May 2004

Improving the care delivered to children with special health care needs

Health care delivered close to home is vitally important, especially when the patient is a child. But how do community pediatric practices adapt to offer the best care when faced with a child who has complex and often, multiple health needs? Reporting in this month's issue of Pediatrics, Dartmouth researchers outline a process designed to help any practice become a state of the art "medical home" for such children.

20 May 2004

Causes of hepatitis and potential therapies that may improve care presented in study

Hepatitis, a potentially serious disease caused by a virus that attacks the liver, is a major problem worldwide. Hepatitis A is generally food-borne, while hepatitis B and C spread primarily through parenteral or sexual routes. Hepatitis B and C can be life-long, potentially deadly chronic infections.

19 May 2004

Caffeinated beverages may benefit some people who are at high-risk for liver disease

According to new research presented today at Digestive Disease Week, drinking caffeinated beverages may benefit some people who are at high-risk for liver disease. Conversely, a study by researchers from India found that soda drinkers, who represent a huge percentage of the American population, may actually have an increased risk of developing esophageal cancer.

19 May 2004

CRT implantable defibrillators significantly reduce hospitalization rates and extend lives

Researchers at the University of Colorado Health Sciences Center have announced the findings of a large-scale clinical trial for patients with late-stage heart failure. Results showed that cardiac resynchronization therapy (CRT) from implantable pacemaker-like devices or CRT combined with an implantable defibrillator (CRT-D), when used in addition to optimal drug therapy, reduced significantly the mortality and first hospitalization rate when compared to drug therapy alone. CRT-D also substantially lowered mortality.

19 May 2004

Network formed to tackle potentially fatal reaction to smallpox vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization.

19 May 2004

$20.7 million to make smallpox vaccine safer

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a five-year, $20.7 million grant to National Jewish Medical and Research Center to lead a consortium of academic medical centers trying to make smallpox vaccines safer for millions of people with atopic dermatitis, also known as eczema.

19 May 2004

Financially burdened patients more likely to die after coronary revascularization

Heart patients who had angioplasty or bypass surgery and felt burdened by medical costs were more than twice as likely to die within a year of their procedure as patients who didn’t have trouble paying for healthcare, according to a study presented today at the American Heart Association’s 5th annual Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

19 May 2004

New book highlights pros and cons of medical use of cannabis

A new book which brings together the relevant science regarding the beneficial effects of cannabis for identified medical conditions and explains many harmful side effects has been launched at Australia's Southern Cross University today.

19 May 2004

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Benitec Ltd. today announced the acquisition of Avocel, Inc. of Sunnyvale, CA, a leading RNAi therapeutics company, and the establishment of its wholly-owned US subsidiary, Benitec, Inc. Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the Hepatitis C virus.

18 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

First filing for zoledronic acid in metabolic bone disease

One 15-minute infusion of the intravenous bisphosphonate zolendronic acid more rapidly reduced the biochemical markers of bone turnover in patients with Paget's disease than was seen in a head-to-head comparison with the oral treatment risedronate (95% vs. 75% response rate).

17 May 2004

Chronic News and Research

KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates

Significant symptom relief reported in clinical trial patients with irritable bowel syndrome

Once-daily treatment with Alvesco (ciclesonide) in asthma patients has no effect on normal adrenal function

Increases in co-payments may reduce the use of medications

Helminthic therapy, using worm eggs to treat patients with inflammatory bowel disorders

Using gene therapy to fight rheumatoid arthritis

New treatment for dry eye syndrome (keratoconjunctivitis sicca)

Pulsed-dye laser surgery for voice disorders better all round

Pacemaker-type device and medicines reduce hospital stays and death rates

Improving the care delivered to children with special health care needs

Causes of hepatitis and potential therapies that may improve care presented in study

Caffeinated beverages may benefit some people who are at high-risk for liver disease

CRT implantable defibrillators significantly reduce hospitalization rates and extend lives

Network formed to tackle potentially fatal reaction to smallpox vaccine

$20.7 million to make smallpox vaccine safer

Financially burdened patients more likely to die after coronary revascularization

New book highlights pros and cons of medical use of cannabis

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

First filing for zoledronic acid in metabolic bone disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News